Metabolon
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$4.0m | Series A | ||
$5.0m | Series A | ||
$8.0m | Series B | ||
N/A | $3.1m | Series C | |
$6.2m | Series C | ||
$13.1m | Series D | ||
$15.0m | Series E | ||
N/A | $5.0m | Early VC | |
$15.0m | Debt | ||
N/A | $7.3m | Debt | |
$72.0m | Growth Equity VC | ||
* | N/A | $25.0m | Late VC |
* | N/A | Grant | |
* | $60.0m | Debt | |
* | N/A | Grant | |
Total Funding | $156m |
Related Content
Recent News about Metabolon
EditMetabolon, Inc. specializes in providing advanced metabolomics solutions, which involve the large-scale study of small molecules called metabolites within cells, biofluids, tissues, or organisms. The company serves a diverse range of clients, including academic researchers, pharmaceutical companies, and government institutions. Operating in the biotechnology and life sciences market, Metabolon offers a comprehensive suite of services from study design and sample collection to data analysis and biological interpretation. The business model is service-based, generating revenue through contracts and collaborations for metabolomic analysis projects. Metabolon leverages its extensive compound library and integrated bioinformatics platform to deliver high-fidelity results, ensuring reliable and actionable insights for its clients. The company has successfully completed over 10,000 projects for more than 1,300 clients, demonstrating its expertise and reliability in the field.
Keywords: Metabolomics, Biotechnology, Data Analysis, Bioinformatics, Research, Pharmaceuticals, Academic, Government, Biological Insights, Compound Library.